New Prognostic and Predictive Markers in Cancer Progression

• Weitere Verfasser: Costantini, Susan (Herausgegeben von), Budillon, Alfredo (Herausgegeben von)
• Format: Elektronisch Buchkapitel
• Sprache: Englisch
• Veröffentlicht: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
• Schlagworte: Medicine; MSI2; OSCC; oral cancer; musashi 2; prognosis; N-cadherin; EMT; breast cancer; new metastasis; eribulin; blood; biomarker; bladder cancer; immune checkpoint inhibitor; CD8+ T effector cells; microRNA; biomarkers; head and neck cancer; laryngeal cancer; prediction; metastasis; lifestyle habit; chemo-/radio resistance; therapeutic target; AKT; AR; castration-resistant prostate cancer (CRPC); MAPK; mTOR; PI3K; prostate cancer; therapeutic resistance; WNT; miRNA; melanoma; melanoma resistance to MAPK/MEK inhibitors; resistance to immune checkpoint inhibitors; TNBC; BRCA1/2; HRR; PDL1; TILs; PI3KCA; PTEN; CTCs; CSC; pancreatic cancer; K-RAS oncogene; oncogene dependency; targeted therapies; genomic mutations; transcriptomics; metabolomics; selenoproteins; cancer; HUB nodes; major histocompatibility complex (MHC); human leukocyte antigen (HLA); antigen processing machinery (APM) molecules; carcinogenesis; tumor predisposition; cancer immunotherapy; pheochromocytoma; paraganglioma; head and neck neoplasms; head and neck tumors; genetic syndromes; mutations; hyperglycemia; cardioncology; nivolumab; cytokines; cardiotoxicity; acetyltransferase; cancer prognosis; NAA10; n/a
• Online-Zugang: DOAB: download the publication; DOAB: description of the publication

Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient's outcome and cancer recurrence probability after initial intervention...